Proteus breaks link with UBS: Split over speed of bringing out new drugs
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.PROTEUS parted company with its joint stockbroker, UBS, yesterday after the USM-quoted biotechnology company disagreed with the City firm on how quickly it could be expected to bring new drugs to the market.
Proteus's shares tumbled 31p to close at 394p, the company's second large fall this year. Last week the market reacted coolly to the announcement of an interim pre-tax loss, marking the shares 19p lower.
The departure of UBS came only four months after its appointment by Proteus. The house was understood to have been selected from a shortlist because of its perceived ability to place shares later this year when further cash is expected to be required. Proteus retains Allied Provincial as its sole broker.
Kevin Gilmore, chairman, said UBS was new to the sector and had not properly understood new fast-track drug development systems, which saved time by overlapping stages of the testing process.
But he added: 'There has been no row. This was a genuine difference of opinion.'
Floated in 1989 at 87p, the shares have soared on hopes for the company's unique computer-aided molecular design systems. It is yet to make any profits and is spending about pounds 5m a year on development.
The company recently formed joint ventures with Medeva and American Home Products.
Proteus hopes to have 10 human and animal products in the first stage of clinical trials by the end of the year. However, it will be at least five years before any of its products for humans have passed through all the regulatory hoops.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments